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Abstract
Glioblastoma (GBM) is the most common and most aggressive brain tumour. Prognosis remains poor, despite the combined
treatment of radio- and chemotherapy following surgical removal. GBM cells coexist with normal non-neoplastic cells,
including endothelial cells, astrocytes and immune cells, constituting a complex and dynamic tumour micro-environment
(TME). Extracellular vesicles (EVs) provide a critical means of bidirectional inter-cellular communication in the TME.
Through delivery of a diverse range of genomic, lipidomic and proteomic cargo to neighbouring and distant cells, EVs can
alter the phenotype and function of the recipient cell. As such, EVs have demonstrated their role in promoting angiogenesis,
immune suppression, invasion, migration, drug resistance and GBM recurrence. Moreover, EVs can reflect the phenotype of
the cells within the TME. Thus, in conjunction with their accessibility in biofluids, they can potentially serve as a biomarker
reservoir for patient prognosis, diagnosis and predictive therapeutic response as well as treatment follow-up. Furthermore,
together with the ability of EVs to cross the blood–brain barrier undeterred and through the exploitation of their cargo, EVs
may provide an effective mean of drug delivery to the target site. Unveiling the mechanisms by which EVs within the GBM
TME are secreted and target recipient cells may offer an indispensable understanding of GBM that holds the potential to
provide a better prognosis and overall quality of life for GBM patients.
Introduction
Glioblastoma (GBM) is the most common, aggressive pri-
mary adult brain tumour, leaving patients with a median
survival rate of 15 months after treatment, while displaying
a high recurrence rate and resistance to therapeutics [1]. The
current treatment for GBM patients includes maximal sur-
gical resection followed by radiotherapy with temozolomide
(TMZ), an oral alkylating chemotherapy drug [2]. Unfor-
tunately, GBM usually recurs at or near the primary site
within months of surgical removal [1]. Considering the low
median survival rate for patients undergoing the current
standardised treatment protocol, the development of new
therapeutic procedures in overcoming GBM is urgently
needed.
GBM exists in constant communication with its sur-
rounding tumour micro-environment (TME) [3]. The GBM
TME is highly heterogeneous, consisting of a multiplex of
both cancerous and non-cancerous cells including endo-
thelial cells (ECs), immune cells, glioma stem-like cells
(GSCs) and astrocytes, as well as non-cellular components
such as the extracellular matrix (ECM) (Fig. 1) [4]. The
TME is becoming increasingly recognised as a crucial
supporter to the progression of GBM, playing a critical role
in the regulation of tumour development [5]. Extracellular
vesicles (EVs) have recently been identified as an important
means of bidirectional communication between the tumour
and the TME [6, 7]. According to the International Society
for Extracellular Vesicles, EVs are cell-released membrane-
bound particles that do not contain a functional nucleus [8].
EVs encapsulate and transfer molecules including lipids,
proteins and nucleic acids, amongst other bioactive mate-
rials, allowing for communication between both neigh-
bouring and distant cells [9]. The transfer of such materials
between cells in the TME, as well as tumour cells, have
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been shown to facilitate several tumour-promoting
mechanisms including angiogenesis, invasion, evasion of
apoptosis and resistance to drugs such as the aforemen-
tioned TMZ as well as bevacizumab, a human monoclonal
antibody targeting vascular endothelial growth factor-A
(VEGF-A) [10, 11].
GBM is typically classified into three subtypes, namely
proneural, classical and mesenchymal, according to the
gene expression of various biomarkers including platelet-
derived growth factor receptor (PDGFR), neurofilament
light chain (NF-L), epidermal growth factor receptor
(EGFR) and CD44, respectively [12]. Unfortunately, the
current gold standard for GBM diagnosis is highly invasive
and unrepresentative of GBMs extreme intra-tumoural het-
erogeneity [13]. As their content seems to reflect that of the
donor cell, EVs have been proposed as potential non-
invasive biomarkers [12]. In addition, their ability to be
detected in the bloodstream, cerebrospinal fluid and urine of
GBM patients make EVs valuable candidates for a liquid
biopsy set up [14]. Furthermore, EVs capability to cross the
blood–brain barrier (BBB) is an important factor in con-
sidering them for the successful delivery of drugs to the
TME and tumour site [15]. Altogether, such potential ability
of EVs to better represent the heterogeneity of the tumour
and the TME thus renders them a desirable and effective
candidate for GBM subtyping and predicting therapeutic
response [12].
Through influencing the TME, EVs contribute con-
siderably to the regulation of tumour progression [16, 17].
Unveiling the impact of EVs in the TME and overall tumour
progression is altogether paramount for the development of
novel and effective treatment strategies against GBM. This
review will thereby underpin the mechanistic interactions
between GBM cells and their stromal counterparts via EVs.
Furthermore, the role EVs could play in GBM therapeutic
resistance will be discussed. Thereafter, the exploitation of
Fig. 1 The cellular
heterogeneity of the
glioblastoma micro-
environment. Constant multi-
directional communication
between glioblastoma cells and
normal stromal cells such as
endothelial cells or astrocytes
allows the tumour to hijack its
surrounding micro-environment,
thus triggering a tumour
supportive phenotype.
Extracellular vesicles have been
recently described as being
directly involved in such
crosstalk, along with diffusible
cytokines and growth factors.
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EVs for GBM subtyping and, in turn, the construction of
personalised, more effective treatments for GBM patients
will be explored.
Extracellular vesicle-based interactions of
glioblastoma cells with stromal counterparts
in the tumour micro-environment
Implication of extracellular vesicles in the neo-
angiogenesis process associated with glioblastoma
development
GBM radical and rapid growth eventually leads to the for-
mation of areas of extreme hypoxia [18]. Such oxygen
deprivation promotes neo-angiogenesis mechanisms in the
GBM TME, in order to provide oxygen and nutrients for
tumour growth and survival. GBM is critically dependent
upon angiogenesis and hence is one of the most highly
vascularised tumours [19]. For angiogenesis to occur, ECs
are required to proliferate, migrate and form tubular struc-
tures [20]. EVs derived from GBM cells have been impli-
cated in EC proliferation, migration and tubulogenesis via
delivery of angiogenic proteins and RNA to microvascular
ECs [21].
Mostly released by hypoxic GBM cells, VEGF-A pro-
motes the proliferation and migration of ECs toward
hypoxic regions of GBM [22]. It has been reported that EVs
containing VEGF-A, secreted from GSCs, trigger angio-
genic properties in ECs in vitro, thereby promoting and
sustaining vasculature in the GBM TME [23]. Furthermore,
Sun et al. observed that EVs derived from GSCs transfected
with miR-21 (GSC–EVmiR-21) promote the ability of ECs to
migrate and form tubular structures. Accordingly, a sig-
nificant reduction in EC tube formation ensued following
the knockdown of VEGF, hence implicating VEGF in the
mediation of GSC–EVmiR-21-associated neo-angiogenesis.
Furthermore, as VEGFR2 is highly accountable for the
downstream angiogenic properties of VEGF, the authors
also showed that the interaction of GSC–EVmiR-21 with ECs
markedly promotes the activation of VEGFR2 in ECs [24].
In the same way, Wang et al. demonstrated in vitro that
miR-26a can be transferred from GSCs to ECs via EVs. It
was shown in vivo that the overexpression of miR-26a in
GSCs enhanced the angiogenic properties of ECs and
tumour growth in nude mice, accompanied by an elevation
in VEGF levels. Indeed, western blotting analysis revealed
that the overexpression of miR-26a induced a reduction in
PTEN, thereby activating the PI3K/AKT pathway. Conse-
quently, it was concluded that miR-26a delivered in
GSC–EVs to ECs triggers the PI3K/AKT signalling path-
way in ECs through inhibition of PTEN, thereby upregu-
lating VEGF and subsequently promoting neo-angiogenesis
[25] (Fig. 2). Other growth factors, such as endothelial
growth factor (EGF), fibroblast growth factor (FGF) and
platelet-derived growth factor (PDGF) have also been
implicated in EV-dependent GBM angiogenesis mechan-
isms [11, 25].
EV-based delivery of long intervening/intergenic non-
coding RNA POU3F3 (lincPOU3F3) as well as long non-
coding RNA CCAT2 (linc-CCAT2) to ECs has also been
observed to trigger angiogenesis in the GBM TME in vitro
and in vivo [26, 27]. GBM–EVs overexpressing linc-
CCAT2 from the U87 GBM cell line were indeed reported
to enhance EC expression of VEGF-A and transforming
growth factor-beta (TGF-β) while inhibiting apoptosis via
activating B cell lymphoma-2 (Bcl-2) and suppressing Bcl2-
associated protein x (Bax) and caspase-3 in vitro [27].
Moreover, long non-coding RNA HOX antisense intergenic
RNA (HOTAIR) was demonstrated to promote neo-
angiogenesis in vitro by inducing the expression of
VEGF-A in GBM cells but also by travelling via EVs from
Fig. 2 Glioblastoma stem cell-derived extracellular vesicles can
stimulate neo-angiogenesis via miR-26a (Adapted from Wang
et al. [25]). Extracellular vesicles derived from glioblastoma stem cells
transfer miR-26a to endothelial cells, consequently inhibiting
phosphatase and tensin homolog (PTEN) and promoting the activation
of the PI3K/AKT pathway. Such activation upregulates the VEGF
expression with consecutive promotion of the neo-angiogenesis
process.
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tumour cells to ECs [28]. Recently, a report, similarly,
showed that the promotion of the neo-angiogenesis process
by miRNAs, including miR-9, delivered via GBM–EVs was
mostly dominated by the downregulation of anti-angiogenic
pathways in recipient ECs [29].
In contrast, EVs containing miR-1 transferred between
GBM cells and the TME have been shown to have tumour
suppressive effects, hence decreasing angiogenesis,
tumourigenicity and invasion in vitro and in vivo [16]. The
overexpression of miR-1 in donor cells in vitro was thus
demonstrated to be loaded into EVs and transported to
recipient cells, then decreasing the recruitment of ECs and
reducing neo-vascularisation in vivo. Accordingly, miR-1
levels were reported to be downregulated in GBM patient
samples [16].
As a result of neo-vascularisation, the subsequent GBM
vasculature markedly differs from that of healthy vascu-
lature, comprising a highly dense, disorganised and leaky
network of vessels [30]. The irregularity of neo-
angiogenesis in GBM results in areas of extreme chronic
hypoxia [31], promoting necrosis and invasion of GBM
cells into healthy tissue in order to evade the adverse con-
ditions [18]. EVs have been suggested as mediators of
hypoxia-driven inter-cellular communication between can-
cer cells and ECs, implicating the importance of EVs in
hypoxic-dependent phenotypic changes of GBM vascu-
lature and consequential invasion. As such, Kucharzewska
et al. demonstrated GBM–EVs, cultured under hypoxic
conditions, to alter the phenotype of ECs in order to induce
angiogenesis ex vivo and in vitro [32]. In addition, hypoxic
GBM cells were shown in vitro to trigger a pro-angiogenic
protease activated receptor (PAR-2)-mediated heparin-
binding EGF signalling, inducing paracrine activation of
ECs via EVs [33]. Finally, as EV-mRNA derived from the
plasma of GBM patients has been shown to reflect the
tumour hypoxic status in vitro and in vivo, it has been
suggested to use EVs as a potential mean of assessing the
oxygenation status of GBM [32].
Altogether, EV-dependent mechanisms seem essential to
the neo-angiogenesis process, which is linked to a global
and integrated re-organisation of the GBM TME. Indeed,
ECs are also known to interact with astrocytes in the GBM
TME, for instance at the BBB. Both cell types communicate
with GBM cells through the EVs, thereby promoting BBB
breakdown, a critical step in the GBM invasion process
[17, 34].
Extracellular vesicle implication in the dynamic
relationship between glioblastoma cells and
astrocytes
Astrocytes are the most abundant glial cells, composing
around 50% of the human brain volume [35]. Consequently,
GBM cell-derived EVs have been implicated in altering the
phenotype of normal astrocytes in the TME to exhibit
tumour-supporting capabilities [17, 36]. In addition,
tumour-associated astrocyte-derived EVs have been shown
to directly impact tumour cells. For instance, it was shown
in vivo that EVs containing miR-19a, delivered from
astrocytes to tumour cells, downregulated PTEN expres-
sion, thereby upregulating brain metastasis outgrowth [37].
Furthermore, it has been reported that a crosstalk between
GBM and astrocytes via EVs is critical in the evasion of
tumour cell apoptosis, thus contributing to GBM aggres-
siveness [36]. Using patient-derived cell lines, Oushy et al.
exposed normal astrocytes to GBM–EVs, showing a con-
secutive generation of a growth-stimulating medium packed
with growth factors (such as VEGF, EGF, FGF, hepatocyte
growth factor (HGF) and colony stimulating factors
(CSFs)), interleukins and chemokines, promoting the
growth of GBM cells in vitro [36].
Accordingly, substantial proteome changes have been
observed in normal astrocytes exposed to GBM–EVs, with
evident interconnectivity with upstream regulators such as
c-Myc, p53, TGF-β1 or fibronectin 1 (FN1), described
before as implicated in tumour expansion [17]. Further-
more, authors observed that the mTOR pathway, with links
to a senescence-associated secretory phenotype (SASP),
could be directly associated with the proteome changes
triggered by GBM–EVs in astrocytes [17]. Authors thus
concluded that GBM cell-derived EVs might induce the
acquisition of SASP in astrocytes in vitro, in order to sup-
port tumour growth.
Furthermore, Oushy et al. observed an increase of
immune response regulators, such as CSF2 and interleukin
10 (IL-10), in the secretome of GBM–EV-stimulated
astrocytes, which might be indicative of a global immuno-
suppressive micro-environment set up, induced by
GBM–EVs via tumour-associated astrocytes. Finally, both
reports by Oushy et al. and Hallal et al. similarly suggested
that pathways including ERK, mammalian target of rapa-
mycin (mTOR), mitogen-activated protein kinases
(MAPKs), AKT and c-Jun N-terminal kinases (JNKs) could
underlie the effects of GBM–EVs on astrocytes (Fig. 3)
[17, 36].
Interestingly, recent reports suggested that GBM–EVs
could instigate the remodelling of astrocytic projections,
thereby contributing to the invasiveness of GBM [36].
Hence, EVs from the U87 GBM cell line were shown to
markedly enhance podosome formation and gelatin matrix
degradation in normal astrocytes in vitro. Consequently,
reports implicated these findings as a possible way via
which BBB breakdown occurs in GBM patients, thereby
contributing to GBM invasion [17]. Taking this into
account, tumour-associated astrocytes have a promising
potential to become therapeutic targets in GBM patients.
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The multiple roles of extracellular vesicles in the
immunosuppressive capabilities of glioblastoma
GBM development is highly attributed to its ability to evade
immune response, with GBM–EVs largely contributing to
the immunosuppressive environment of GBM. GBM-
derived EVs have been associated with the re-
programming of microglia through the transfer of func-
tional miR-21 in vivo. Using the GL261 mouse glioma cell
line, it was shown that the mRNA targets of miR-21, such
as BTG Anti-Proliferation Factor 2 (Btg2), were down-
regulated in microglia upon the uptake of GBM–EVs. As
Btg2 is known to downregulate cyclin D1 activity, the
delivery of miR-21 via EVs seems to re-program microglia
into a proliferative mode. Authors suggested that such effect
on microglia should influence the shaping of the GBM
TME [38].
More importantly, GBM cell-derived EVs have been
shown to stimulate a tumour-promoting M2 phenotype in
microglia, as opposed to an immune supportive M1 phe-
notype [39]. GBM–EVs were therefore reported to transfer
miR-451 and miR-21 to microglia cells in vitro, stimulating
cell proliferation and leading to a decrease in c-Myc
expression and consecutive polarisation to a M2 phenotype
in the recipient cells, with increased expression of key
markers such as IL-6 and tissue inhibitor of
metalloproteinases-1 (TIMP-1). Through fluorescent track-
ing of the EVs, authors observed a similar transfer from
GBM cells to microglia in vivo, with increased levels of
miR-21 associated with a decrease of the c-Myc mRNA
levels in brain cells [40]. Considering the wide range of
genes regulated by c-Myc, authors thus concluded that such
inhibition in immune cells is not an on–off switch in gene
activation but is rather related with a global shift towards
expression patterns associated with the activation of a
tumour supportive phenotype.
More reports have demonstrated a link between EV-
miRNAs and immuno-suppression in GBM. Indeed,
hypoxia-induced GBM cells were reported to stimulate the
differentiation of functional myeloid-derived suppressor
cells (MDSCs) via delivery of EVs containing miR-29a and
miR-92a both in vitro and in vivo [41]. In addition, hypoxic
GBM-derived EVs containing miR-1246 were demon-
strated to facilitate the formation of an immunosuppressive
GBM TME through inducing M2 macrophage polarisation
in targeting telomeric repeat-binding factor 2-interacting
protein 1 (TERF2IP), thereby activating the signal trans-
ducer and activator of transcription 3 (STAT3) pathway and
inhibiting the nuclear factor kappa B (NF-κB) pathway [42].
In the same way, GSC-derived EVs appear to promote
monocytes to adopt an immunosuppressive M2 phenotype
and induce the expression of programmed death-ligand 1
(PD-L1), in part mediated by STAT3. Indeed, Gabrusiewicz
et al. reported that GBM patient-infiltrating CD14+ cells
and monocytes treated with GSC–EVs showed increased
phosphorylation of STAT3 linked to upregulation of PD-L1
Fig. 3 Extracellular vesicle-
mediated crosstalk between
glioblastoma cells and
astrocytes supports tumour
growth. a Normal astrocytes
exposed to glioblastoma (GBM)
cell-derived extracellular
vesicles (EVs) produce a tumour
growth-stimulating secretome
including vascular endothelial
growth factor (VEGF),
epidermal growth factor (EGF),
fibroblast growth factor (FGF),
colony stimulating factors
(CSFs), Interleukins 10 and 19
(IL-10 and IL-19) (Inspired by
Oushy et al. [36]). b GBM cell-
derived EVs influence the p53
and MYC signalling pathways
in astrocytes, with consecutive
acquisition of a senescence-
associated secretory phenotype
(SASP) in order to support
tumour growth (Inspired by
Hallal et al. [17]).
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expression [43]. Furthermore, GSC-derived EVs have also
been implicated in mediating CD3+ T-cell suppression
through inducing a monocytic MDSC/tumour-promoting
phenotype in monocytes in vitro [44].
The effects of the GBM cell-derived EVs on the PD1/
PD-L1 pathway also impact T-cell infiltration in the tumour
and brain parenchyma [45, 46]. It has been demonstrated
via in vitro and in vivo experiments that PD-L1 at the
surface of GBM–EVs could prevent the activation and
proliferation of T cells. Moreover, a remarkable correlation
was found between PD-L1 DNA in circulating EVs and
tumour volumes of up to 60 cm3 in GBM patient samples,
suggesting the use of EV PD-L1 DNA as a biomarker for
GBM. Although Ricklefs et al. conducted these experiments
using GSCs, it was notably pointed out that PD-L1 is
expressed by a variety of immune cells in the TME,
including MDSCs, macrophages and microglia, and thus
may also be significant contributors to the elevated levels of
PD-L1 EVs. Conclusively, these findings demonstrate the
binding of PD-L1 to PD1 on EVs to be a plausible
mechanism by which GBM evades T-cell infiltration in the
TME, thereby promoting GBM immuno-suppression,
growth and invasion (Fig. 4) [46].
In addition, Grimaldi et al. demonstrated that microglia-
derived EVs containing IFNγ could downregulate the
expression of anti-inflammatory genes in microglia treated
with IL-4 in vitro. Furthermore, it was shown that
IFNγ–EVs could decrease the anti-inflammatory phenotype
of tumour-associated myeloid cells and, consequently, sig-
nificantly decreases the tumour size and neurotoxicity in the
brains of mice with glioma. Such findings are suggestive of
the use of microglia EVs in transference of neuroprotective
signals to tumour-associated myeloid cells, thereby restor-
ing the homoeostatic phenotype of microglia in GBM and
thus homoeostasis of the CNS [47].
Overall, it appears that selective targeting of GBM–EVs
involved in the conversion of M1 to M2 phenotype could
thus be considered for the treatment of GBM. Mechanisms
to promote the re-polarisation of an M1 phenotype in cells,
possibly involving EVs, also need to be further investigated.
Extracellular vesicles help matrix re-
organisation during glioblastoma tumour
progression
The ECM makes up the inter-cellular space in the CNS,
comprising 20% of an adult brain and consisting of a
multiplex of fibrous proteins including collagen, fibronectin
and laminin, which are significant structural components of
the ECM, as well as an abundance of proteoglycans and
hyaluronic acid (HA) [48]. Degradation of the ECM is a
critical step in the process of angiogenesis, followed by
migration of ECs in forming new blood vessels [49]. ECM
degradation and remodelling found in GBM patients creates
a scaffold for inter-cellular communication within the TME
and cell migration, triggered in response to angiogenic sti-
muli [50]. During GBM development ECM components
such as HA and proteoglycans become overexpressed, or
take on a tumour-supporting phenotype, subsequently
resulting in GBM growth and invasion [19, 35, 51].
Notably, Hallal et al. found that the degradation of the
ECM, which facilitates cell migration and invasion, may be
induced by GBM–EVs, upregulating the formation of
Fig. 4 Glioblastoma cell-
derived extracellular vesicles
regulate the immune response
to tumour growth via the PD-
L1/PD1 signalling.
Extracellular vesicle (EV)-
associated PD-L1 can directly
bind PD1 receptor at the surface
of infiltrating T cells in the
brain, thus inhibiting their
activation and consequently
supporting immunosuppression
(Inspired by Ricklefs et al. [46]).
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podosomes in normal astrocytes. Podosomes are important
mediators of ECM interactions and promote ECM degra-
dation through local proteolysis [17]. Moreover, GBM–EVs
were demonstrated in vitro to contribute to the modulation
of the ECM composition by decreasing p53 expression in
astrocytes [17]. This loss in p53, paired with the promotion
of a SASP, increases the level of FN1 [52]. Indeed, the
receptor for FN1 is a integrin α5 and β1 (α5β1) dimer,
known to be upregulated in GBM and associated with GBM
invasion and poor prognosis [53]. Although the mechanism
by which α5β1 contributes to GBM migration and invasion
is not entirely known, it has been suggested to operate by
means of interacting with matrix metallopeptidases (MMP)
2 [54]. Crucially, MMPs are known to be responsible for the
degradation of many ECM proteins, including collagen,
fibronectin and proteoglycans. Indeed, EVs have been
implicated in the regulation of MMP activity [55]. For
instance, EVs derived from chronically irradiated glioma
cells were shown by Baulch et al. to markedly enhance
MMP-2 activity in GBM cell lines. This demonstrated a
possible role of EVs in the arising of a treatment-resistant
subpopulation of cells after radiotherapeutic treatment
which exhibited a profoundly more aggressive phenotype
[56]. Furthermore, Oushy et al. suggested MMP-9 to be
secreted by EV-treated astrocytes, thereby enhancing GBM
invasion [36]. Also, it was demonstrated that the transfer of
mir-26a in EVs from GSCs to ECs elevates MMP-2 and
MMP-9 levels, thereby promoting ECM degradation and
upregulation of angiogenesis [57, 58]. Furthermore, several
reports on cancer cells have established CD44 to capture
MMP-2 and MMP-9 at the cell surface, where they locally
digest the surrounding ECM during extravasation, conse-
quently supporting GBM aggressiveness [59, 60].
Accordingly, HA, an integral ECM component, has been
strongly associated with GBM invasion and overall poor
patient prognosis [51]. The binding of HA to its pre-
dominant receptor, CD44, was shown in vitro and in vivo to
interact with MMPs [61], thereby driving tumour progres-
sion and upregulation of the PI3K/AKT and ERK signalling
pathways, inducing pro-migratory effects and apoptotic
resistance in GBM [62]. Notably, HA is more abundant in
the GBM ECM than healthy brains while CD44 is often
found to be upregulated in GBM tumours [60, 63]. In the
same way, CD44 has been observed to be highly expressed
in EVs derived from respective GBM cell lines [12].
Interestingly, the EV-mediated release of CD44 has pre-
viously been associated with the EGFRvIII mutant. Skog
et al. observed EGFRvIII oncoprotein and mRNA in 47% of
GBM tissue samples and found EGFRvIII in the EVs of
28% of serum samples from the same patients [64]. Further,
Choi et al. reported EVs derived from parental U373 glioma
cells expressing EGFRvIII to highly overexpress CD44
[65]. Thus, EGFRvIII may modulate GBM invasiveness
through re-programming GBM–EVs to interact with the
ECM and thereby modulate ECM components [65]. The
present evidence indicates a significant role of EVs in
inducing TME components to inherit a phenotype in favour
of ECM modulation.
Glioblastoma extracellular vesicles break
through the blood–brain barrier
The BBB functions as a defensive interface between the
brain and circulating blood, thereby allowing for the reg-
ulation of movement of cells, molecules and ions as well as
limiting access of toxins and pathogens [66]. The main
structure is predominantly comprised of ECs joined by tight
junctions, with pericytes and astrocytes playing a crucial
additional supporting role [66]. BBB is significantly altered
by GBM growth, thus leading to subsequent dysfunction
[67, 68]. Accordingly, GBM cell-derived EVs expressing
Semaphorin3A (Sema3A) at their surface have been shown
of being capable of disrupting the endothelial barrier
integrity via binding to the Sema3a receptor neuropilin1
[69]. Authors observed that EVs derived from GSCs could
induce re-organisation of the cell–cell adhesion molecule
VE-cadherin in ECs leading to an increased permeability
upon EV uptake in vitro. Interestingly, normal cell-derived
EVs were not able to induce such changes. Furthermore,
in vivo assays revealed that EVs derived from GBM
patients’ blood carried Sema3A, consequently inducing a
significant vascular leakage, as opposed to EVs derived
from healthy volunteers [69]. Several other mechanisms yet
to be fully described might be involved in the GBM–EVs
capabilities to interact with the BBB. They might include
transcytosis via which brain metastasis-derived EVs
apparently can breach the intact BBB [70]. Advanced
in vitro and in vivo BBB models indeed revealed that
tumour cell-derived EVs are able to decrease the RAB7
levels in ECs, consecutively improving the efficacy of their
own transport through the barrier via inhibiting the RAB7-
driven transport to lysosomes. Interestingly, authors
observed that the astrocytic component would preferentially
uptake tumour cell-derived EVs promoting the BBB breach
and consecutive tumour progression. Such observation thus
suggested a central role of astrocytes in the BBB integrity
regulation upon interactions with tumour-derived EVs [35].
Astrocytic end feet, which are indeed directly involved in
the structure and tightness of the BBB, are displaced during
GBM development, consequently causing loss of astrocyte-
vascular coupling and formation of openings in the barrier
[17, 71]. The profound change that has been observed in the
astrocyte–blood vessel interactions during GBM progres-
sion, partly caused by tumour cell–EVs, might eventually
have important consequences on the brain vasculature
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organisation, with GBM cells taking control on vascular
tone [71].
Hypoxia is also a predominant driver of BBB disruption
in GBM, as it directly alters the tight junctions between
ECs. Indeed, the remarkable proliferation of ECs, found in
GBM consecutively to increasing hypoxia, causes disrup-
tion of tight junctions, leading to the loss of BBB integrity
[34]. Accordingly, VEGF-A found in hypoxic GBM–EVs
has been demonstrated to increase BBB permeability in
both in vitro and in vivo models. In the report published by
Zhao et al., GBM–EV–VEGF-A is shown to be able to alter
the expression and organisation of both claudin-5 and
occludin, two of the main regulators of tight junctions, in
brain microvascular ECs [34, 72]. Authors thus suggest that
such disruption of the BBB via hypoxic GBM–EV could be
directly involved in tumour expansion both locally and at
distant sites in the brain.
Indirectly, such hypoxia-driven context has also been
reported to induce changes in pericytes, which are known to
be involved in the BBB structure and function. Indeed,
Kucharzewska et al. observed that ECs conditioned with
hypoxic GBM–EVs can stimulate pericyte migration in a
paracrine way, while direct addition of GBM–EVs could
not cause similar results [32]. Such data suggested that
pericytes responded to a paracrine factor secreted by
GBM–EV-conditioned ECs rather than to a direct stimu-
lating signal from GBM cells. Nevertheless, EV-dependent
inter-cellular crosstalk involving pericytes in the GBM
micro-environment is yet to be described. However, as such
interactions are better described in other cancer types where,
for instance, tumour cell-derived EVs have been reported to
promote the transition of pericytes into cancer-associated
fibroblasts, one might expect similar mechanisms to happen
in a GBM context [73].
Altogether, such alterations of the BBB structure and
organisation have direct consequences on the delivery of
therapeutics to the brain. The permeability of the BBB has
therefore been highly studied and used in order to improve
the delivery of drugs to the brain in GBM patients [15, 74].
EVs, having the ability to cross the BBB, may be con-
sidered for a safer, non-invasive drug delivery system in
GBM patients. Finally, owing to their natural origin, EVs
are at low risk of being immunologically rejected [4].
Preliminary results on EV-driven interactions
between tumour cells and neurons in the
GBM micro-environment
Even though neurons are the most valuable and vulnerable
components of the SNC, research on GBM cell–neuron
interactions is still limited. Interestingly, a very elegant
study reported by Gao et al. revealed that glioma cells can
also interact with neurons in the TME [75]. Indeed, in vivo
evidence showed that synaptic activity of neurons increased
following uptake of tumour-derived EVs. Accordingly
neuronal activity has been reported to be potentially
involved in glioma progression, via the activity of
neuroligin-3 (NLGN-3), which appears to promote tumour
progression through, at least partly, the PI3K-mTOR path-
way, with links to focal adhesion kinase activation [76].
Nlgn-3 knockout has thus been observed to significantly
reduce tumour growth in vivo. Furthermore, authors
reported that an increase of the tumour cell proliferation
upon treatment with conditioned medium from optogeneti-
cally stimulated acute cortical slices was incompletely
abrogated following Nlgn-3 knockout. Such results, even
though they show evidence of an important role of NLGN-3
in the neuronal support to glioma growth, also suggest that
other factors, potentially including EVs, might be secreted
by neurons to promote tumour expansion [76]. Altogether,
it thus appears that the new set of data reported by Gao et al.
clearly suggest a potential involvement of EVs in a glioma
cells–neurons crosstalk during glioma growth, via enhanced
neuronal activity [75].
Extracellular vesicles and glioblastoma
therapeutics
Glioblastoma extracellular vesicles as means of
therapeutic resistance
The current treatments for GBM patients are of limited
benefit, which can be highly accredited to GBM hetero-
geneity and invasiveness, as well as the ability of GBM to
rapidly acquire resistance to therapies such as the alky-
lating agent TMZ. GBM response to TMZ is modulated
by O-6-methylguanine-DNA methyltransferase (MGMT),
which drives TMZ resistance when overexpressed by
tumours [77]. EVs have been demonstrated to play a
significant role in TMZ resistance via delivery of MGMT
mRNA. Indeed, it was observed by Yu et al. that EVs
derived from reactive astrocytes containing MGMT
mRNA can be functionally translated into MGMT in
recipient GBM cells, thereby promoting TMZ resistance
both in vivo and in vitro (Fig. 5) [78].
In addition, growing evidence is unravelling the regula-
tion of GBM chemo-resistance through EV-miRNAs
[79, 80]. For instance, GBM–EV miR-93 and miR-193
have been reported to promote TMZ resistance in vitro
through enhancing cell cycle quiescence by decreasing
cyclin D1 [81]. In a recent study conducted by Yin et al.,
circulating EVs from GBM patients were found to have
higher levels of miR-1238 as compared to EVs from con-
trols. Authors reported that EV miR-1238 promoted TMZ
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resistance in sensitive GBM cells in vitro and in vivo, most
likely involving the EGFR-PI3K-Akt-mTOR pathway (Fig. 5)
[82]. In the same way, previous study conducted by Yin
et al. also demonstrated the transfer of miR-151a via EVs in
enhancing sensitivity of TMZ to resistant GBM cell lines
through inhibiting XRCC4-mediated DNA repair [83].
Furthermore, miR-9 was also found to be upregulated in
TMZ-resistant cells. Indeed, EVs of mesenchymal stem
cells were shown to sensitise resistant GBM cells to TMZ
through transfer of anti-miR-9, reversing the expression of
multidrug transporters by reducing upregulation of miR-9.
Such results actually demonstrate the possibility of utilising
anti-miR delivery via EVs in therapeutics [84].
Interestingly, inhibition of EV uptake by GBM cells has
been observed to be associated with reduced TMZ resis-
tance. Indeed, as chemokine (C-C motif) receptor 8 (CCR8)
was identified as an EV receptor at the surface of GBM
cells, via glycans exposed on EVs and the soluble chemo-
kine ligand C-C Motif Chemokine Ligand 8 (CCL18),
inhibition of CRR8 using small molecule R243 was
demonstrated to interrupt the uptake of EVs by GBM cells,
thereby sensitising GBM cells to TMZ [85]. Consequently,
treatment with R243 was observed to delay tumour growth
in nude mice treated with TMZ. Similarly, our lab recently
showed that bevacizumab, an anti-angiogenic therapeutic
designed to inhibit VEGF signalling, could be encapsulated
by GBM cells and presented at the surface of EVs secreted
by the respective GBM cells. The inhibition of EV pro-
duction was then shown to increase the effect of bev-
acizumab in GBM cells. We thus suggested that a combined
therapeutic strategy of administering bevacizumab, together
with prevention of local EV communication could enhance
treatment of GBM patients [10, 19, 86].
In addition, EVs are hypothesised to be a principal driver
of GBM heterogeneity. Through exchanging oncogenic
cargo, EVs help alter the phenotype of various cells within
the TME, including both tumour and stromal cells [87, 88].
In addition, all GBM subtypes are often present in the same
tumour bulk simultaneously, thereby supporting resistance
to treatments [89]. As they theoretically present the
Fig. 5 Extracellular vesicles of
the glioblastoma micro-
environment directly support
temozolomide resistance. a
Extracellular vesicles (EVs)
derived from astrocytes in a
reactive state consecutive to
tumour growth can contain
MGMT mRNA. Once up-taken
by glioblastoma (GBM) cells,
such EVs thus induce TMZ
resistance via the inhibition of
cell apoptosis (Adapted from Yu
et al. [78]). b TMZ-resistant
GBM cells can produce EVs
carrying miR-1238 that, once
up-taken by TMZ-sensitive
GBM cells, inhibits caveolin-1
(CAV1), thus interfering with
CAV1-driven inhibition of
EGFR phosphorylation. PI3K-
AKT-mTOR pathways
consecutively get activated,
supporting TMZ resistance
(Inspired by Yin et al. [82]).
TMZ Temozolomide.
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molecular background to each GBM subtype, GSCs are
widely associated with GBM heterogeneity [90, 91]. For the
same reasons, they have been reported as essential drivers
of GBM recurrence consecutive to a mesenchymal transi-
tion of the tumour molecular background [89]. It thus has
been reported that GBM–EVs may support the expansion of
the mesenchymal subtype within the tumour bulk, thereby
stimulating recurrence [12, 65, 87].
Extracellular vesicles as a biomarker reservoir for
glioblastoma diagnosis, prognosis and follow-up
As they are known to, at least partly, mirror the physiology
of the donor cell and in turn alter the physiology of recipient
cells, EVs are viewed as potential proficient indicators of
changes within the TME. Accordingly, miRNA signatures
and mRNA variants found in GBM–EVs have been found
to be unique to GBM patients [64]. In the same way, EVs
have been reported to reflect the oxygenation status of GBM
cells and thus the development status of a patient’s tumour
[25, 32]. Furthermore, as MGMT levels in parental cells as
well as in patients seem to be mirrored by the MGMT
mRNA in the respective EVs, such EV-associated MGMT
mRNA could potentially serve as a real-time biomarker of
chemotherapeutic response [92]. EVs have hence been put
forward as reservoirs of potential biomarkers in GBM
diagnosis, prognosis and treatment follow-ups, on account
of their cargo specificity and accessibility in biofluids. In
looking at the proteomic content of EVs, it has been sug-
gested that GBM tumour subtyping can be established and
thus may be used in directing and developing more effective
and personalised GBM treatments. Our recent publication
has indeed revealed that the proteomic content of EVs can
mirror the molecular signature and invasiveness potential of
GBM cell lines in vitro. Moreover, according to our data,
EVs may contain reliable protein markers for the aggressive
mesenchymal GBM subtype in particular, including CD44
[12, 93, 94]. In addition, we also observed that GBM cell-
derived EVs could contain information regarding the
metabolic status of the cell of origin. Accordingly, a recent
report on the potential of the EV metabolic cargo as a
diagnostic mean revealed interesting correlations with our
own EV proteomic cargo-based sub-classification of GBM
cell lines [95].
Following such idea, a protein signature has recently
been identified in EVs from hypoxic U87 GBM cells
in vitro, in direct association with hypoxia-inducible factor-
1α (HIF-1α), transcription factor network and HIF-1 sig-
nalling [96]. The proposed hypoxic protein signature
included insulin-like growth factor-binding protein 3
(IGFBP3), coagulation factor III, carbonic anhydrase 9
(CA9), glucose transporter 1 (SLC2A1), and progesterone
receptor membrane component 1 (PGRMC1) mRNAs,
which have previously demonstrated an involvement in
GBM hypoxia and progression. As expected, this hypoxic
GBM–EV signature was found to be most closely asso-
ciated with the GBM mesenchymal subtype, thus suggest-
ing that such GBM–EV hypoxic signature may be used for
GBM mesenchymal subtyping [97]. Consistently, Treps
et al. reported a marked increase of the VEGF-A expression
in circulating EVs of GBM patients compared with those of
healthy donors. Altogether, and in accordance with the EVs
ability to cross the BBB, authors then argued that EV-
derived VEGF-A could constitute a possible GBM diag-
nosis biomarker [23].
Interestingly, it appears that the expression levels of EV
specific markers in the vesicles, such as CD63, CD9, heat
shock protein 70 (HSP70) or annexin A2, could also be
indicative of the GBM aggressiveness. We, and others, have
reported that such marker expression changes are in
accordance with the molecular subtype of the cells of origin.
For instance, EVs produced by proneural GBM cells seem
to show very low levels of CD9, CD63 and CD81 expres-
sion, as compared with EVs derived from the aggressive
mesenchymal GBM cells [12, 65].
In addition, a recent study conducted by Osti et al.
observed an elevated concentration of EVs in the plasma of
GBM patients compared with the plasma of healthy con-
trols. Following surgical removal of the tumour, the
increased level of EVs dissipated to a concentration on par
with the healthy controls. Interestingly, the increase in EV
plasma concentration was resumed upon GBM recurrence
[14]. Such results call attention to the diagnosis and prog-
nosis impact of measuring EV concentration in patients’
biofluids, as a complement to describing the EV cargo.
Use of extracellular vesicles as potential drug
vehicles for glioblastoma treatment
The benefits of therapeutic drugs for GBM patients are
partly impeded by the limited penetration of the BBB and
poor infiltration of the GBM tumour and TME, leading to
the inability to achieve effective concentrations at the site of
the tumour [98]. As a result, there is a dire demand for
effective drug administration to the GBM tumour site.
Several reports have thus set forth the advantages of EVs
as potential drug delivery vehicles, mostly for their intrinsic
abilities for bypassing the BBB [4]. In addition, as men-
tioned previously, their natural origin poses only low risk of
immunogenic reactions and hepatic clearance [4]. More-
over, due to the lipid bilayer membrane, EVs can tolerate
degrading environments and for this reason may be
exploited to enhance the concentrations of drugs delivered
to the target tumour site [99]. Through manipulation of their
cargo, EVs could therefore be highly valuable for GBM
treatment. Erkan et al. reported that EVs genetically
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engineered to carry the suicide gene mRNA and protein
cytosine deaminase fused to uracil phosphoribosyltransfer-
ase could significantly decrease tumour expansion in mice
bearing GBM tumours obtained by implantation of U87
GBM cells [100]. Finally, as some of their cargo con-
stituents might underlie their cellular tropism, EVs could, in
theory, be manipulated into highly selective drug vehicles,
hence limiting side effects and toxicity on normal stromal
cells in the brain micro-environment [101]. Interestingly,
glycans at the vesicle surface has thus been observed to
favour an uptake of EVs by CCR8-positive GBM cells
[100, 102, 103]. Overall, it appears that personalised and
targeted therapeutic strategies could greatly benefit from
EVs in the aim to conserve healthy brain tissue typically
harmed by drug toxicity during GBM treatment [101].
Final remarks
Overall, in accordance with all the reports reviewed here,
GBM–EVs seem to have the potential to unravel some of
the numerous mysteries surrounding GBM high aggres-
siveness, complex molecular and cellular heterogeneity and
discouraging resistance to therapies. But not only studying
EVs can offer a glimpse into the yet to be fully described
crosstalk between cancer cells and their micro-environment,
it also has the potential to eventually accelerates diagnosis
in a significant way via a liquid biopsy set up. Also, loading
therapeutics into/onto EVs could help break on through the
BBB to reach the target effectively. However, due to the
extreme intra- and inter-tumoural heterogeneity of both
GBM tumours and EV subpopulations, there still is a long
way to go before reaching complete understanding of the
complex involvement of EVs in the GBM micro-
environment.
The EV field is also facing multiple limiting challenges,
including reaching a consensus regarding method for vesi-
cle concentration from biofluids and cell culture medium.
Indeed, it appears that results of EV analysis are directly
impacted in accordance with the methods employed to
concentrate and analyse EVs [107]. Moreover, low yield
and important contamination by non-EV particles dramati-
cally impact the quality of EV samples [104]. A consensus
on new methods for correcting such issues is hence urgently
needed in the EV community in order to obtain bona fide
and comparable research [105].
In addition, it seems critical to identify the mechanisms
underlying the specific production, secretion and uptake of
oncogenic and anti-tumourigenic cargo of EVs. Such
understanding may hold the potential to illuminate cell–cell
communication in the TME. In the same way, revealing the
method of EV biogenesis and uptake may provide insight
for therapeutics delivery. Finally, a therapeutic strategy to
impede the secretion of EVs carrying oncogenic material
may decrease invasion, immune suppression and drug
resistance and thereby improve GBM patient prognosis.
Again, this ultimate goal will require further extensive
research into still unknown, yet essential, mechanisms such
as EV cargo sorting [106].
Overall, although huge progress has been made the last
two decades in understanding the roles of EVs in cancer
progression in general, including extensive description of
the EV cargo, there is now a need for improved and fine
characterisation of the GBM–EVs, in respect of the various
vesicle subpopulations and in a molecular subtype/patient-
specific way. Especially in the case of the highly hetero-
geneous GBM tumours, associating better methods/proto-
cols to extensive research on the vesicles biology thus seem
to be the only way forward to eventually incorporate the
EVs into a clinical set up for quicker and more accurate
GBM diagnosis and effective, more personalised,
treatments.
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